AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7000
-0.1100 (-6.08%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.8100
Open1.8400
Bid1.71 x 2200
Ask1.92 x 1000
Day's Range1.6500 - 1.9000
52 Week Range1.0000 - 3.7500
Volume120,195
Avg. Volume79,371
Market Cap30.047M
Beta (3Y Monthly)3.08
PE Ratio (TTM)N/A
EPS (TTM)-0.85
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.38
Trade prices are not sourced from all markets
  • GlobeNewswire29 minutes ago

    AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today provided a clinical development and strategic corporate update.

  • What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
    Simply Wall St.last month

    What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?

    If you want to know who really controls AzurRx BioPharma, Inc. (NASDAQ:AZRX), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...

  • GlobeNewswire2 months ago

    AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has initiated the Company's Phase II OPTION study to investigate MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). The Phase II multi-center study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head comparison against the current porcine enzyme replacement therapy standard of care.  Planned enrollment is expected to include approximately 30 CF patients, with study completion anticipated in 2019.

  • GlobeNewswire2 months ago

    AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced that it is acquiring royalty and milestone obligations to its lead drug candidate MS1819-SD, a recombinant lipase for exocrine pancreatic insufficiency, from Protea Biosciences Group (“Protea”), who initiated Chapter 11 proceedings in December 2017. Following an auction held on November 27, 2018, AzurRx emerged as the successful bidder for contractual rights to milestone and royalty payments under a Stock Purchase and Sale Agreement previously executed by AzurRx and Protea.

  • Zacks Small Cap Research3 months ago

    AZRX: 3Q:18 Financial and Operational Summary

    Highlights for the period and to date include participation in investment conferences, presentation of favorable trial data, acceptance of a new IND and a nod of approval from the Therapeutics Development Network for their cystic fibrosis trial protocol. Financial results for the quarter reflect the interim between the chronic pancreatitis study and the cystic fibrosis study and show an expected dip in cash burn. Research and development expenses were up 21% compared to the prior year period as AzurRx established its R&D function in the United States and recognized related costs, but were down sequentially, representing a break between the CP and CF studies.

  • GlobeNewswire3 months ago

    AzurRx BioPharma to Present at Upcoming Investor Conferences

    BROOKLYN, N.Y., Dec. 04, 2018 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant.

  • Zacks Small Cap Research5 months ago

    AZRX: Final Results from Phase II EPI Trial

    Other endpoints were also positive, including Bristol stool scale, number of daily evacuations and weight of stool, which were consistent with the CFA results. CMO Dr. Pennington was pleased at the high level of statistical significance of the results and announced his expectation that the Phase IIb portion of the trial in cystic fibrosis (CF) will begin later in 2018. This compares to the dose response of just over 16% that was achieved in the Phase 1/2a FLIP110 study.

  • Zacks Small Cap Research6 months ago

    AZRX: Phase 2 Cystic Fibrosis Study to Start

    The company’s most important announcement year to date has been the completion of the Phase 2a trial for MS1819 in late June. Trial results were favorable and provided evidence of safety and efficacy for the Yarrowia lipolytica-derived lipase in exocrine pancreatic insufficiency (EPI). The company also raised $10 million in a public offering underwritten by Oppenheimer.

  • Zacks Small Cap Research8 months ago

    AZRX: AzurRx Announces Completion of Phase 2a MS1819 Trial

    AzurRx BioPharma, Inc. (AZRX) announced the completion of the Phase IIa MS1819-SD trial on June 29, 2018 and expects to provide a formal report presenting the data in the fall of 2018 at an as yet unidentified scientific conference. As a reminder, the trial was a Phase 2a open-label, dose escalation study conducted in France, Australia and New Zealand with the goal of identifying the safety of escalating doses and dose response. It was conduted in conjuntion with Mayoly Spindler Laboratories and launched November 17, 2016.

  • Zacks Small Cap Research10 months ago

    AZRX: AzurRx Raises Capital After Confirming Results

    AzurRx BioPharma, Inc. (AZRX) provided an update regarding its Phase 2a trial for MS1819 for treatment of chronic pancreatic insufficiency (EPI) The April 23rd release identified consistent progress in the Phase 2a trial for MS1819 with respect to patient enrollment, safety and dose response. The trial is targeting 12 – 15 patients and is enrolling in France, Australia and New Zealand. Current screening and enrollment trends are on track for a 1H:18 study completion.

  • Benzinga10 months ago

    Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...

  • Zacks Small Cap Research10 months ago

    AZRX: French Sites to Help Achieve 1H:18 Enrollment Goal

    AzurRx BioPharma, Inc. (AZRX) filed their fiscal year 2017 10-K on March 16th providing a financial update on the company’s performance. The filing caps off a year that saw progression of the Phase IIa trial for MS 1819 for treatment of exocrine pancreatic insufficiency (EPI), new patent protection filings and new personnel and board additions. In 2018, the company received approval for a clinical site in France and continued to add new patients.

  • ACCESSWIRElast year

    Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC

    CLEARWATER, FL / ACCESSWIRE / March 2, 2018 / The AzurRx Biopharma, Inc. (NASDAQ: AZRX) research report is available on Stock Market Manager ( smm.global ): Research Report Here About AzurRx, Biopharma, ...